Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 3
2022 3
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis.
Lo Russo G, Prelaj A, Dolezal J, Beninato T, Agnelli L, Triulzi T, Fabbri A, Lorenzini D, Ferrara R, Brambilla M, Occhipinti M, Mazzeo L, Provenzano L, Spagnoletti A, Viscardi G, Sgambelluri F, Brich S, Miskovic V, Pedrocchi ALG, Trovo' F, Manglaviti S, Giani C, Ambrosini P, Leporati R, Franza A, McCulloch J, Torelli T, Anichini A, Mortarini R, Trinchieri G, Pruneri G, Torri V, De Braud F, Proto C, Ganzinelli M, Garassino MC. Lo Russo G, et al. Among authors: franza a. J Immunother Cancer. 2023 Jun;11(6):e006833. doi: 10.1136/jitc-2023-006833. J Immunother Cancer. 2023. PMID: 37286305 Free PMC article. Clinical Trial.
Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer.
Antonelli L, Ardizzone D, Tachibana I, Adra N, Cary C, Hugar L, Sexton WJ, Bagrodia A, Mego M, Daneshmand S, Nicolai N, Nazzani S, Giannatempo P, Franza A, Heidenreich A, Paffenholz P, Saoud R, Eggener S, Ho M, Oswald N, Olson K, Tryakin A, Fedyanin M, Naoun N, Javaud C, Cazzaniga W, Nicol D, Gerdtsson A, Tandstad T, Fizazi K, Fankhauser CD; EAU-YAU Penile and Testis Cancer Working Group. Antonelli L, et al. Among authors: franza a. J Clin Oncol. 2023 Dec 1;41(34):5296-5305. doi: 10.1200/JCO.23.00443. Epub 2023 Sep 1. J Clin Oncol. 2023. PMID: 37656935
Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study.
Antonelli L, Ardizzone D, Ravi P, Bagrodia A, Mego M, Daneshmand S, Nicolai N, Nazzani S, Giannatempo P, Franza A, Heidenreich A, Paffenholz P, Saoud R, Eggener S, Ho M, Oswald N, Olson K, Tryakin A, Fedyanin M, Naoun N, Javaud C, Fizazi K, King JM, Adra N, Douglawi A, Cary C, Sweeney C, Fankhauser CD. Antonelli L, et al. Among authors: franza a. Eur J Cancer. 2023 Mar;182:144-154. doi: 10.1016/j.ejca.2022.12.032. Epub 2023 Jan 20. Eur J Cancer. 2023. PMID: 36787661 Free article.
Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trial.
Ligorio F, Lobefaro R, Fucà G, Provenzano L, Zanenga L, Nasca V, Sposetti C, Salvadori G, Ficchì A, Franza A, Martinetti A, Sottotetti E, Formisano B, Depretto C, Scaperrotta G, Belfiore A, Vingiani A, Ferraris C, Pruneri G, de Braud F, Vernieri C. Ligorio F, et al. Among authors: franza a. Int J Cancer. 2024 Jan 1;154(1):114-123. doi: 10.1002/ijc.34701. Epub 2023 Aug 24. Int J Cancer. 2024. PMID: 37615485
Risk assessment of thromboembolic events in hospitalized cancer patients.
Nichetti F, Ligorio F, Montelatici G, Porcu L, Zattarin E, Provenzano L, Franza A, Lalli L, de Braud F, Platania M. Nichetti F, et al. Among authors: franza a. Sci Rep. 2021 Sep 14;11(1):18200. doi: 10.1038/s41598-021-97659-9. Sci Rep. 2021. PMID: 34521927 Free PMC article.
Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study.
Niger M, Nichetti F, Casadei-Gardini A, Rizzato MD, Pircher C, Bini M, Franza A, Rimini M, Burgio V, Sposetti C, Fornaro L, Rapposelli IG, D'Amico FE, Aprile G, Vivaldi C, Frassineti GL, Milione M, Leoncini G, Cappetta A, Vasile E, Fassan M, Morano F, Perrone F, Tamborini E, Pruneri G, Lonardi S, Mazzaferro V, Pietrantonio F, Di Bartolomeo M, de Braud F. Niger M, et al. Among authors: franza a. Int J Cancer. 2022 Oct 15;151(8):1310-1320. doi: 10.1002/ijc.34182. Epub 2022 Jul 9. Int J Cancer. 2022. PMID: 35723131 Free article.
12 results